Cargando…

High Efficacy of Therapeutic Equine Hyperimmune Antibodies Against SARS-CoV-2 Variants of Concern

SARS-CoV-2 variants of concern show reduced neutralization by vaccine-induced and therapeutic monoclonal antibodies; therefore, treatment alternatives are needed. We tested therapeutic equine polyclonal antibodies (pAbs) that are being assessed in clinical trials in Costa Rica against five globally...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreira-Soto, Andres, Arguedas, Mauricio, Brenes, Hebleen, Buján, Willem, Corrales-Aguilar, Eugenia, Díaz, Cecilia, Echeverri, Ann, Flores-Díaz, Marietta, Gómez, Aarón, Hernández, Andrés, Herrera, María, León, Guillermo, Macaya, Román, Kühne, Arne, Molina-Mora, José Arturo, Mora, Javier, Sanabria, Alfredo, Sánchez, Andrés, Sánchez, Laura, Segura, Álvaro, Segura, Eduardo, Solano, Daniela, Soto, Claudio, Stynoski, Jennifer L., Vargas, Mariángela, Villalta, Mauren, Reusken, Chantal B. E. M., Drosten, Christian, Gutiérrez, José María, Alape-Girón, Alberto, Drexler, Jan Felix
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451950/
https://www.ncbi.nlm.nih.gov/pubmed/34552949
http://dx.doi.org/10.3389/fmed.2021.735853
Descripción
Sumario:SARS-CoV-2 variants of concern show reduced neutralization by vaccine-induced and therapeutic monoclonal antibodies; therefore, treatment alternatives are needed. We tested therapeutic equine polyclonal antibodies (pAbs) that are being assessed in clinical trials in Costa Rica against five globally circulating variants of concern: alpha, beta, epsilon, gamma and delta, using plaque reduction neutralization assays. We show that equine pAbs efficiently neutralize the variants of concern, with inhibitory concentrations in the range of 0.146–1.078 μg/mL, which correspond to extremely low concentrations when compared to pAbs doses used in clinical trials. Equine pAbs are an effective, broad coverage, low-cost and a scalable COVID-19 treatment.